#United States #FlyteHealth #Medicare Access #New Canaan, Connecticut #Cardio-Kidney Care

FlyteHealth's Recognition in Medicare ACCESS Program

FlyteHealth, a forefront leader in precision cardio-kidney metabolic care, has recently been highlighted by the Centers for Medicare & Medicaid Services (CMS) for its effective eCKM management strategies. This recognition precedes the launch of the ACCESS model, a new 10-year Medicare payment demonstration set to commence on July 1, 2026. With this initiative, FlyteHealth aims to advance chronic care through innovative and scalable solutions that address key health issues like hypertension, dyslipidemia, obesity, central adiposity, and prediabetes. The focus on these upstream conditions is critical, as they significantly contribute to the development of severe health issues such as heart disease, stroke, kidney failure, and diabetes.

A Distinctive Approach to Care

What sets FlyteHealth apart is its national strategy to manage cardio-kidney metabolic diseases, which revolves around two core pillars:

1. Precision Lifestyle Management: This involves a continuous and personalized behavioral intervention framework that utilizes remote monitoring and AI-powered digital tools, supplemented by coordinated team-based care. This system is designed to foster sustainable lifestyle changes tailored to individual health profiles.

2. Expert Clinical Medication Management: This method applies a disciplined, evidence-based approach to crafting personalized care plans. It emphasizes medication optimization for various conditions including hypertension and diabetes, based on patient responses and best practice standards.

The integration of these components is managed by a dedicated team of community health workers, medical doctors, nurse practitioners, registered nurses, registered dietitians, and coaches, consistently achieving remarkable clinical outcomes across various at-risk factors.

Proven Outcomes and Effectiveness

The impact of FlyteHealth's model is substantiated by compelling data demonstrating enhanced health metrics:

• - Significant reductions in blood pressure (over 16%), LDL cholesterol (more than 9%), and HbA1c levels (up to 13%).
• - Average weight loss exceeding 14% after 24 months with a non-GLP-1 only formulary (with GLP-1s, the average reaches over 18%).
• - An impressive 86% medication adherence rate validated independently through pharmacy claims.

In a longitudinal study conducted over 12 months, researchers at Millian reported notable cost savings associated with FlyteHealth's approach combined with strong adherence patterns, affirming the effectiveness of the program.

Tailored for the 65+ Demographic

With a proven history of supporting Medicare-age adults, FlyteHealth's framework is ideally equipped to deliver measurable outcomes that align with the ACCESS program's objectives. The combination of a virtual clinical intervention and intensive behavioral strategies sets the stage for success in managing chronic conditions among older adults.

Looking ahead, FlyteHealth is eager to collaborate with CMS and other stakeholders to extend its impactful model to millions of Americans battling cardiometabolic diseases, harnessing its clinical expertise, digital innovations, and scalable infrastructures to contribute significantly to health outcomes across the nation.

About FlyteHealth

Founded by pioneers in obesity medicine, FlyteHealth specializes in precision cardio-kidney metabolic care, addressing prediabetes, diabetes, hypertension, hyperlipidemia, obesity, and related comorbidities. Employing advanced data analytics and AI, FlyteHealth enables the development of cost-efficient and scalable care models throughout the United States. The company's commitment is directed towards achieving measurable health outcomes while optimizing medication use and minimizing overall healthcare costs.

For more information, visit www.flytehealth.com.